APAC Exosome Research Products Market - Industry Trends And Forecast To 2030

APAC Exosome Research Products Market - Industry Trends And Forecast To 2030

Asia-Pacific exosome research products market is projected to register a substantial CAGR of 40.3% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030.

Market Segmentation:

Asia-Pacific Exosome Research Products Market, By Product (Instruments, and Consumables), Indication (Cancer and Non-Cancer), Application (Therapeutics and Diagnosis), End Users (Hospitals, Clinical Testing Laboratories, Research Centers, Pharmaceutical and Biotechnology Company, Academic Institutes and Others), Distribution Channel (Third Party Distributors, Online, Direct Tender, and Others), Country (China, Japan, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, New Zealand Vietnam, Taiwan, and Rest of Asia-Pacific) Industry Trends and Forecast to 2030

Market Drivers:
• Growing prevalence of cancer, chronic inflammation, autoimmune disease, Lyme disease, and other chronic degenerative diseases
• Increasing investments in pharmaceutical R&D and life sciences research

Market Players:

The key market players in Asia-Pacific colorectal cancer diagnostics market are listed below:
• Hologic Inc.
• Luminex Corporation
• Thermo Fisher Scientific
• Agilent Technologies, Inc.
• Microgentas, Cell Guidance Systems LLC
• QIAGEN
• FUJIFILM Irvine Scientific(a subsidiary of FUJIFILM Holdings Corporation),
• CUSABIO TECHNOLOGY LLC
• Norgen Biotek Corp.
• Miltenyi Biotec
• Novus Biologicals
• Beckman Coulter, Inc.
• JSR Micro NV
• Hitachi, Ltd.
• INOVIQ
• Audubon Bioscience

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.

Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.